De Novo Pharmaceuticals
A more rational approach to drug design
De Novo is a world leader in in-silico, de novo drug design.

De Novo’s technology offers the following advantages to drug developers:-
  • lower cost in-silico design reduces wasted effort in synthesis and HTS

  • rapid – typically less than 6 months target to hits

  • lower molecular weight hits – allows greater scope for medicinal chemists to optimise molecules

  • novel – explore trillions of drug like molecules

  • patentable hit molecules – composition of matter claims free from existing IP

De Novo’s technology is derived from a substantial body of research over thirty years in the Department of Pharmacology at the University of Cambridge.

Learn More

Print this page

Recent News
De Novo Agrees Med Chem Synthesis Deal
De Novo Launches Academic Access Programme
De Novo Takes SkelGen to Japan
De Novo Launches ‘Stand-Alone; SkelGen
De Novo signs first academic licence with the University of Hertfordshire
De Novo Pharmaceuticals announces a Drug Discovery Partnership agreement with Achaogen
De Novo Pharmaceuticals Ltd. Announces New Partnering Opportunity in Diabetes
De Novo Pharmaceuticals Ltd. Announces New Therapeutic Focus In the Area Of Metabolic Diseases And Appoints New Scientific Advisory Board.
De Novo Pharmaceuticals Ltd Announces Drug Discovery Collaboration Agreement with Genzyme
De Novo launches Reflex, a major upgrade to its in silico drug design platform